Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis

Journal of Clinical Pharmacology

Volumn 44, Issue 8, 2004, Pages 866-872

  Burgos Vargas, Rubén ^a   Foeldvari, Ivan ^b   Thon, Angelika ^c   Linke, Ronald ^d   Tuerck, Dietrich ^d  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b Allgemeines Krankenhaus Eilbek   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Juvenile rheumatoid arthritis (JRA); Meloxicam; Pediatrics; Pharmacokinetics

Indexed keywords

CORTICOSTEROID; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL TOXICITY; GEOMETRY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CYCLOOXYGENASE INHIBITORS; FEMALE; GERMANY; HALF-LIFE; HUMANS; MALE; MEXICO; THIAZINES; THIAZOLES;

EID: 3242796465     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004267589     Document Type: Article

References (25)

1. Manners PJ, Bower C: Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002;29:1520-1530.
2. Cassidy JT: Medical management of children with juvenile rheumatoid arthritis. Drugs 1999;58:831-850.
3. Dowd JE, Cimaz R, Fink C: Non-steroidal anti-inflammatory drug-induced gastrointestinal injury in children. Arthritis Rheum 1995;38:1225-1231.
4. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C: Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-433.
5. Turck D, Roth W, Busch U: A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996;35(Suppl. 1):13-16.
6. Davies NM, Skjodt NM: Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 1999;36:115-126.
7. Hanft G, Türck D, Scheuerer S, Sigmund R: Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. Inflamm Res 2001;50(Suppl. 1):S35-S37.
8. Foeldvari I, Burgos-Vargas R, Thon A, Tuerck D: High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1079-1083.
9. Busch U, Heinzel G, Narjes HH: The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID) in man. Eur J Clin Pharmacol 1995;48:269-272.
10. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-538.
11. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al: Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-528.
12. Yasar Ü, Eliasson E, Dahl M-L, Johansson I, Ingelman-Sundberg M, Sjöqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Common 1999;254:628-631.
13. London SJ, Sullivan-Klose T, Daly AK, Idle JR: Lung cancer risk in relation to the CYP 2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 1997;7:401-404.
14. Garcia-Martin E, Martinez C, Ladero JM, Gamito FJG, Agundez JAG: High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001;57:47-49.
15. Olkkola KT, Naunuksela E-L, Korpela R: Pharmacokinetics of postoperative intravenous indomethacin in children. Pharmacol Toxicol 1989;65:157-160.
16. Korpela R, Olkkola KT: Pharmacokinetics of intravenous diclofenac sodium in children. Eur J Clin Pharmacol 1990;38:293-295.
17. Bertin L, Rey E, Pons G, Mathist JL, Richard MO, Chretien P, et al: Pharmacokinetics of tiaprofenic acid in children after a single oral dose. Eur J Clin Pharmacol 1991;41:251-253.
18. Mäkelä A-L, Olkkola KT, Mattila MJ: Steady state pharmacokinetics of piroxicam in children with rheumatoid diseases. Eur J Clin Pharmacol 1991;41:79-81.
19. Nahata MC, Durrell DE, Powell DA, Gupta N: Pharmacokinetics of ibuprofen in febrile children. Eur J Clin Pharmacol 1991;40:427-428.
20. Rey A, Pariente-Khayat A, Gouyet L, Vauzelle-Kervroedan F, Pons G, D'Athis P, et al: Stereoselective disposition of ibuprofen enantiomers in infants. Br J Clin Pharmacol 1994;38:373-375.
21. Dequeker I, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, et al: Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. BrJ Rheumatol 1998;37:946-951.
22. Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Begaud B, et al: Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998;37:937-945.
23. Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortesen E, Lines CR, et al: The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 2001;15:1-9.
24. Deeks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Br Med J 2002;325:619-626.
25. St. Rose E, Ferrandiz M, Kiss M, Forre O, Vehe R, Higgins G, et al: Steady-state plasma concentrations of rofecoxib in children (ages 2-5 years) with juvenile rheumatoid arthritis (JRA) [abstract OP0094]. EULAR 2001.